You are viewing the site in preview mode
Skip to main content
|
Features
|
MVI-(n = 43)
|
MVI + (n = 19)
|
p Value
|
|---|
|
Non-enhancement
| | | |
|
Mosaic architecture
| | | |
|
Yes
|
7 (16.3%)
|
1 (5.3%)
|
0.233
|
|
Intralesional fat
| | | |
|
Yes
|
16 (37.2%)
|
4 (21.1%)
|
0.210
|
|
Intratumor hemorrhage
| | | |
|
Yes
|
2 (4.7%)
|
3 (15.8%)
|
0.138
|
|
Iso/hyper-intense SI (T1WI)
| | | |
|
Yes
|
13 (30.2%)
|
3 (15.8%)
|
0.231
|
|
T2-DW mismatch
| | | |
|
Yes
|
1 (2.3%)
|
3 (15.8%)
|
0.047
|
|
Morphology (T2WI)
| | | |
|
Round shape
|
20 (46.5%)
|
10 (52.6%)
|
0.250
|
|
Lobulated
|
20 (46.5%)
|
6 (31.6%)
| |
|
Irregular shape
|
3 (7.0%)
|
3 (15.8%)
| |
|
Enhancement without HBP
| | | |
|
AP hyper-enhancement
| | | |
|
Yes
|
32 (74.4%)
|
14 (73.7%)
|
0.951
|
|
Washout
| | | |
|
No enhancement
|
4 (9.3%)
|
1 (5.3%)
|
0.804
|
|
Enhance and without Washout
|
7 (16.3%)
|
4 (21.1%)
| |
|
Enhance and washout
|
32 (74.4%)
|
14 (73.7))
| |
|
Rim enhancement
| | | |
|
Yes
|
5 (11.6%)
|
9 (47.4%)
|
0.006
|
|
Capsule enhancement
| | | |
|
Enhance and complete
|
16 (37.2%)
|
5 (26.3%)
|
< 0.001
|
|
Enhance and Uncomplete
|
23 (53.5%)
|
2 (10.5%)
| |
|
No enhance
|
4 (9.3%)
|
12 (63.2%)
| |
|
AP halo signs
| | | |
|
Yes
|
5 (11.6%)
|
9 (47.4%)
|
0.006
|
|
HBP
| | | |
|
HBP high uptake
| | | |
|
Yes
|
17 (39.5%)
|
2 (10.5%)
|
0.022
|
|
HBP halo sign
| | | |
|
Yes
|
4 (9.3%)
|
8 (42.1%)
|
0.013
|
|
HBP morphology
| | | |
|
Round shape
|
29 (67.4%)
|
4 (21.1%)
|
< 0.001
|
|
Lobulated
|
11 (25.6%)
|
5 (26.3%)
| |
|
Irregular shape
|
3 (7.0%)
|
10 (52.7%)
| |
|
HBP spicule sign
| | | |
|
Yes
|
3 (7.0%)
|
12 (63.2%)
|
< 0.001
|
|
HBP brush sign
| | | |
|
Yes
|
4 (9.3%)
|
8 (42.1%)
|
0.003
|
- Except where indicated otherwise, data are number (%) of patients. Categoric imaging variables were analyzed by the chi-square test. SI, signal intensity; T2-DW, T2-weighted and diffusion-weighted imaging; T2WI, T2-weighted; AP, arterial phase; HBP, hepatobiliary phase
